Tearsheet

Onconetix (ONCO)

Market Price (3/30/2026): $1.52 | Market Cap: $0.5 Mil
Sector: Health Care | Industry: Biotechnology

Onconetix (ONCO)

Market Price (3/30/2026): $1.52
Market Cap: $0.5 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -854%	Weak multi-year price returns 2Y Excs Rtn is -122%, 3Y Excs Rtn is -162%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -6.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -778%
1	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.		Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -68%, Rev Chg QQuarterly Revenue Change % is -57%
2			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1187%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1187%
3			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2322%
4			High stock price volatility Vol 12M is 458%
5			Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 83%
6			Key risks ONCO key risks include [1] a critical cash shortage and going concern risk, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -854%
1	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.
2	Weak multi-year price returns 2Y Excs Rtn is -122%, 3Y Excs Rtn is -162%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -6.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -778%
4	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -68%, Rev Chg QQuarterly Revenue Change % is -57%
5	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1187%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1187%
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2322%
7	High stock price volatility Vol 12M is 458%
8	Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 83%
9	Key risks ONCO key risks include [1] a critical cash shortage and going concern risk, Show more.

Valuation, Metrics & Events

	3/30/26	2025	2024	2023	2022
Share Price CYE	$1.52	$1.56	$53.55	$673.20	$3,740.00
Market Cap CYE ($ Mil)	0.5	0.5	1.5	0.9	3.4
Total Debt ($ Mil)	0.0	0.0	9.4	9.9	0.0
Total Cash ($ Mil)	5.2	5.2	0.6	4.6	25.8
Enterprise Value ($ Mil)	-4.7	0.5	10.9	10.8	3.4
Valuation Ratios
P/S TTM	0.6	0.6	0.6	15.1	-
P/EBIT TTM	-0.0	-0.0	-0.0	-0.0	-0.2
P/E TTM	-0.0	-0.0	-0.0	-0.0	-0.2
P/FCF TTM	-0.0	-0.1	-0.1	-0.1	-0.4
Sector Ratios
P/S TTM (Sector)	3.3	4.0	3.8	4.2	4.6
P/EBIT TTM (Sector)	-1.6	-1.8	-1.4	-1.4	-1.3
P/E TTM (Sector)	-1.6	-1.9	-1.7	-1.6	-1.3
P/FCF TTM (Sector)	-1.5	-1.7	-1.5	-1.5	-1.7

	3/30/26	2025	2024
Share Price CYE	$1.52	$1.56	$53.55
Market Cap CYE ($ Mil)	0.5	0.5	1.5
Total Debt ($ Mil)	0.0	0.0	9.4
Total Cash ($ Mil)	5.2	5.2	0.6
Enterprise Value ($ Mil)	-4.7	0.5	10.9
Valuation Ratios
P/S TTM	0.6	0.6	0.6
P/EBIT TTM	-0.0	-0.0	-0.0
P/E TTM	-0.0	-0.0	-0.0
P/FCF TTM	-0.0	-0.1	-0.1
Sector Ratios
P/S TTM (Sector)	3.3	4.0	3.8
P/EBIT TTM (Sector)	-1.6	-1.8	-1.4
P/E TTM (Sector)	-1.6	-1.9	-1.7
P/FCF TTM (Sector)	-1.5	-1.7	-1.5

	ONCO	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-57.4%	7.3%
Rev Chg LTM	-67.7%	6.7%
Rev Chg 3Y Avg	2,074.8%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-778.2%	18.6%
CFO/Rev LTM	-1,187.0%	20.7%
Net Inc Mgn	-1,721.0%	12.8%
VALUATION	VERY LOW
P/S	0.6	3.1
P/CFO	-0.0	14.8
P/FCF	-0.0	19.4
P/E	-0.0	23.7
STABILITY	VERY GOOD
Debt/Equity	0.10	0.22
Cash/Assets	0.21	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Patients in Proclarix Clinical Study	over 800	3192025	Link
Number of Licensed Biomarkers for PancreaSure™ Test	3	9222025	Link
Proclarix Sales Revenue	67380	12312023	Link

Recent
3/12/2026	Earnings Release	Rev: $0.0 Mil (A) vs. $null (E) EPS: 12.58 (A) vs. $- (E)
3/25/2026	Stock Split	Ratio: 1-for-5
Upcoming
5/11/2026	Earnings Release	Rev: - EPS: -
6/01/2026	Earnings Release	Rev: - EPS: -

Price Chart

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Onconetix (ONCO) stock has lost about 85% since 11/30/2025 because of the following key factors:

1. Poor Financial Performance and "Going Concern" Doubt. Onconetix experienced a substantial decline in its financial performance, with revenue decreasing by 67.70% to $815,371 in 2025 compared to the previous year, and reported losses of -$15.53 million. This weakened financial position prompted the company's auditor, Malone & Bailey, PLLC, to express "going concern" doubt in the 10-K report filed on March 13, 2026, for the period ending December 31, 2025, indicating significant uncertainty about the company's ability to continue operations.

2. Dilutive Reverse Stock Splits to Maintain Nasdaq Listing. To address issues with Nasdaq's minimum bid price requirement, Onconetix implemented a 1-for-5 reverse stock split effective March 25, 2026. This followed earlier reverse stock splits, including a 1-for-85 split in June 2025 and a 1-for-40 split in September 2024. Such actions, while aimed at preserving the public listing, have historically eroded investor confidence, with previous splits leading to average single-day declines of -22.27%.

Show more

Stock Movement Drivers

Fundamental Drivers

The -86.0% change in ONCO stock from 11/30/2025 to 3/29/2026 was primarily driven by a -76.7% change in the company's P/S Multiple.

(LTM values as of)	11302025	3292026	Change
Stock Price ($)	13.90	1.94	-86.0%
Change Contribution By:
Total Revenues ($ Mil)	1	1	-33.4%
P/S Multiple	3.2	0.7	-76.7%
Shares Outstanding (Mil)	0	0	-9.9%
Cumulative Contribution			-86.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/29/2026

	Return	Correlation
ONCO	-86.0%
Market (SPY)	-5.3%	12.5%
Sector (XLV)	-8.7%	16.1%

Fundamental Drivers

The -86.8% change in ONCO stock from 8/31/2025 to 3/29/2026 was primarily driven by a -63.6% change in the company's Shares Outstanding (Mil).

(LTM values as of)	8312025	3292026	Change
Stock Price ($)	14.65	1.94	-86.8%
Change Contribution By:
Total Revenues ($ Mil)	1	1	-38.6%
P/S Multiple	1.3	0.7	-40.8%
Shares Outstanding (Mil)	0	0	-63.6%
Cumulative Contribution			-86.8%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/29/2026

	Return	Correlation
ONCO	-86.8%
Market (SPY)	0.6%	10.6%
Sector (XLV)	5.2%	11.2%

Fundamental Drivers

The -98.2% change in ONCO stock from 2/28/2025 to 3/29/2026 was primarily driven by a -99.0% change in the company's Shares Outstanding (Mil).

(LTM values as of)	2282025	3292026	Change
Stock Price ($)	105.14	1.94	-98.2%
Change Contribution By:
Total Revenues ($ Mil)	2	1	-56.4%
P/S Multiple	0.2	0.7	329.8%
Shares Outstanding (Mil)	0	0	-99.0%
Cumulative Contribution			-98.2%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/29/2026

	Return	Correlation
ONCO	-98.2%
Market (SPY)	9.8%	8.4%
Sector (XLV)	-2.1%	7.9%

Fundamental Drivers

The -100.0% change in ONCO stock from 2/28/2023 to 3/29/2026 was primarily driven by a null change in the company's P/S Multiple.

(LTM values as of)	2282023	3292026	Change
Stock Price ($)	19890.00	1.94	-100.0%
Change Contribution By:
Total Revenues ($ Mil)	0	1	9.2233720368547763E17%
P/S Multiple	∞	0.7
Shares Outstanding (Mil)	0	0	-99.7%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/29/2026

	Return	Correlation
ONCO	-100.0%
Market (SPY)	69.4%	6.3%
Sector (XLV)	18.4%	5.8%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
ONCO Return	-	-98%	-82%	-92%	-97%	-59%	-100%
Peers Return	12%	-37%	13%	-8%	3%	-2%	-25%
S&P 500 Return	27%	-19%	24%	23%	16%	-5%	72%
Monthly Win Rates [3]
ONCO Win Rate	-	36%	17%	8%	25%	0%
Peers Win Rate	45%	35%	45%	47%	43%	53%
S&P 500 Win Rate	75%	42%	67%	75%	67%	33%
Max Drawdowns [4]
ONCO Max Drawdown	-	-98%	-84%	-96%	-97%	-94%
Peers Max Drawdown	-21%	-50%	-18%	-27%	-36%	-8%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-5%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: EXAS, MYGN, OPK, VTRS, PFE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)

How Low Can It Go

Unique Key	Event	ONCO	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-99.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	37580.4%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days

Compare to EXAS, MYGN, OPK, VTRS, PFE

In The Past

Onconetix's stock fell -99.7% during the 2022 Inflation Shock from a high on 3/15/2022. A -99.7% loss requires a 37580.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Onconetix (ONCO)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

AI Analysis | Feedback

Here are 1-3 brief analogies for Onconetix (ONCO):

Like a specialized Moderna, but focused on diverse infectious disease vaccines (including universal flu), and also selling an approved prostate therapy.
Imagine a smaller, emerging GSK, heavily focused on next-generation vaccines, but also with an existing FDA-approved prostate medication.

AI Analysis | Feedback

Entadfi: An FDA-approved, once-daily pill combining finasteride and tadalafil for treating benign prostatic hyperplasia.
Streptococcus pneumoniae vaccine candidate: A vaccine in development to prevent infectious middle ear infections in children and pneumonia in the elderly.
Universal flu vaccine: A vaccine in development designed to provide protection from all virulent strains of influenza.
Norovirus S&P nanoparticle versatile virus-like particle (VLP) vaccine platform: A licensed platform used for developing vaccines for various infectious diseases, including Marburg and monkeypox.

AI Analysis | Feedback

Onconetix (ONCO), as a biotechnology and pharmaceutical company, primarily sells its products to other companies within the healthcare supply chain, rather than directly to individual consumers. Major customers for its FDA-approved drug Entadfi and its vaccine candidates would typically fall into the following categories:

Pharmaceutical Wholesalers and Distributors: These companies purchase pharmaceutical products and vaccines directly from manufacturers like Onconetix and distribute them to pharmacies, hospitals, and other healthcare providers.
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
Large Retail Pharmacy Chains: These major pharmacy networks acquire drugs and other health products for dispensing to patients. While often supplied through distributors, they represent a significant end-point customer type for pharmaceutical manufacturers.
- CVS Health (CVS)
- Walgreens Boots Alliance, Inc. (WBA)
Healthcare Providers and Government Agencies: This category includes large hospital systems, integrated delivery networks, and governmental bodies that purchase pharmaceuticals and vaccines for direct patient care or public health initiatives.
- HCA Healthcare, Inc. (HCA) - (Example of a publicly traded hospital operator)
- Government agencies and public health organizations (e.g., national health services, Centers for Disease Control and Prevention) - (These are typically governmental bodies and not publicly traded companies)

AI Analysis | Feedback

null

AI Analysis | Feedback

Karina M. Fedasz, Interim Chief Executive Officer and Interim Chief Financial Officer

Ms. Fedasz has over two decades of experience in financial management, capital raising, and strategic planning. Her background includes CFO positions across various industries, including biotech, and she served as Head of Business Development at Evofem Biosciences. She also managed the initial public offering for IDW Media Holdings and provided expertise to early-stage companies focused on artificial intelligence and health tracking. Ms. Fedasz holds an MBA from Columbia Business School and a BA from UCLA.

James Sapirstein, Executive Chairman

Mr. Sapirstein has over 35 years of experience in the healthcare sector, specifically in pharmaceutical company leadership. He currently serves as the President, CEO, and Chairman of Entero Therapeutics, Inc. (NASDAQ: ENTO) and holds board positions with other healthcare companies.

Andrew Oakley, Chairman of the Board and Lead Independent Director

Mr. Oakley is an experienced pharmaceutical and biotech industry professional. He previously held CFO positions at Autolus Therapeutics plc (NASDAQ: AUTL) from 2018 to 2022, Sosei Group (TSE:4565) from 2017 to 2018, as well as Vectura Group plc, and Actelion Ltd, where he led the finance function for over a decade. He also serves as a board member for several privately held Biotech companies.

Dr. Thomas Meier, Director

Dr. Meier possesses close to 25 years of experience as a life-science and biotech entrepreneur, executive manager, and board member. He is the Managing Partner of Viopas Venture Consulting GmbH and was a co-founder of Santhera Pharmaceuticals Holding AG, where he served as CEO for eight years and contributed to its initial public offering on the Swiss Stock Exchange. He has served as chairman or board member for several other biotech companies and advised on the merger that formed Onconetix.

Timothy R. Ramdeen, Independent Non-Executive Director

Mr. Ramdeen has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation. Since June 2022, he has been the founder and managing partner of Dharma Capital Advisors, an investment and advisory firm focused on early-stage private and public companies. He was also a co-founder, chief investment officer, and portfolio manager at Sixth Borough Capital Management, a multi-stage, event-driven hedge fund.

AI Analysis | Feedback

Key Risks to Onconetix (ONCO)

Clinical Development and Regulatory Approval Risk: A significant portion of Onconetix's future growth and valuation is tied to the successful development and regulatory approval of its pipeline products, including its streptococcus pneumoniae vaccine candidate, universal flu vaccine, and various vaccines utilizing the norovirus S&P nanoparticle versatile virus-like particle vaccine platform for infectious diseases like Marburg and monkeypox. The inherent challenges in clinical trials, such as unexpected safety issues, lack of efficacy, or delays in regulatory processes, pose substantial risks to the company's ability to bring these candidates to market. Failure at any stage of development could lead to significant financial losses and severely impact the company's long-term prospects.
Market Competition: Onconetix faces considerable competition for both its FDA-approved product, Entadfi (a combination of finasteride and tadalafil for benign prostatic hyperplasia), and its various vaccine candidates in development. The market for BPH treatments includes established therapies and potential new entrants. Similarly, the vaccine market is highly competitive, dominated by large pharmaceutical companies with extensive research and development capabilities, manufacturing infrastructure, and established distribution channels. Onconetix's ability to gain market share and achieve commercial success for its products will depend on their differentiation, efficacy, safety, and pricing strategies in highly competitive environments.
Intellectual Property Protection: The ability to secure, maintain, and enforce strong intellectual property rights, primarily patents, is critical for Onconetix's business model. For Entadfi, robust patent protection is essential to prevent generic competition. For its pipeline of vaccine candidates, the successful development and commercialization depend heavily on the company's ability to obtain and defend patents covering its technologies and products. Any challenges to Onconetix's patents, the inability to secure new patents, or infringement by third parties could significantly erode the value of its assets, reduce potential revenues, and hinder its competitive position.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here are the addressable market sizes for Onconetix's main products and services:

Entadfi (Benign Prostatic Hyperplasia - BPH treatment): The global benign prostatic hyperplasia drugs market was valued at USD 6.36 billion in 2024 and is projected to reach USD 10.13 billion by 2032. Another estimate for the global benign prostatic hyperplasia treatment market size was USD 13.0 billion in 2025, with projections to reach USD 18.9 billion by 2034. The U.S. Benign Prostatic Hyperplasia Treatment Market was estimated at USD 4.18 billion in 2025 and is projected to reach USD 6.32 billion by 2033. North America held a significant share of the global BPH market, accounting for over 34.8% in 2025.
Streptococcus pneumoniae vaccine (Pneumococcal vaccine): The global pneumococcal vaccine market size was estimated at USD 8.07 billion in 2023 and is projected to reach USD 12.19 billion by 2030. Another report valued the global pneumococcal vaccine market at USD 8.5 billion in 2024, with an anticipation to reach USD 15.5 billion by 2035. North America held the largest share of the global market, with 36.7% in 2024.
Universal flu vaccine: While a specific addressable market size for a "universal flu vaccine" is not currently differentiated in the provided data, the overall global influenza vaccine market size was valued at USD 7.2 billion in 2024 and is estimated to reach USD 12.8 billion by 2033. North America dominated this market, holding over 53.4% market share in 2024.
Marburg vaccine: The global Marburg virus infection market is projected to reach $740 million by 2033. Another estimate valued the global Marburg virus disease therapeutics market at approximately USD 100.9 million in 2025, with a projection to reach around USD 164.5 million by 2035.
Monkeypox vaccine: The global monkeypox vaccine and treatment market size was valued at USD 86.75 million in 2023 and is projected to reach approximately USD 228.51 million by 2033. Another source indicates the market was valued at USD 103.5 million in 2024 and is projected to reach USD 225.12 million by 2032. North America currently dominates the monkeypox vaccine and treatment market.
Norovirus vaccine: The global norovirus vaccines market size reached USD 1.34 billion in 2024 and is projected to expand to USD 6.38 billion by 2033. North America dominated the global norovirus vaccines market, accounting for approximately 42% of the global market share in 2024, with a market value of USD 563 million.

AI Analysis | Feedback

null

AI Analysis | Feedback


The search results provide a lot of information about Onconetix (ONCO), formerly Blue Water Biotech (BWV). I need to carefully filter and organize this information into the requested categories for the last 3-5 years (roughly 2021-2026).

**Verification Step:** The background provided confirms that Onconetix (ONCO) was formerly Blue Water Biotech, Inc. and changed its name in December 2023, and is headquartered in Cincinnati, Ohio. The search results consistently refer to Onconetix (ONCO) and Blue Water Biotech (BWV) and mention Cincinnati, Ohio, and their focus on biotechnology, men's health, and oncology, aligning with the background information. There are also mentions of "Bluewater Bio", but these results clearly describe a water technology company, not a biotechnology company, so I will filter those out. For example, are about "Bluewater Bio" (water technology company), which is distinct from "Blue Water Biotech" / "Onconetix".

Let's break down the information by category:

** Share Repurchases:**
*   Blue Water Vaccines Inc. (BWV) announced a share repurchase program to buy back up to 5 million shares on November 9, 2022. No information found for Onconetix after the name change, or for any completed repurchases, only the authorization.

** Share Issuance:**
*   **September 2025:** Onconetix completed a $12.9 million private placement financing through the issuance of Series D Convertible Preferred Stock and warrants. Approximately $9.3 million was paid in cash, and the remainder offset existing debts. This Series D Preferred Stock is initially convertible into 4,362,827 shares of common stock.
*   **October 2024:** Onconetix announced a private placement of Series C Convertible Preferred Stock and warrants for approximately $2.0 million. The Series C Preferred Stock is initially convertible into 776,590 shares of common stock.
*   **October 2024:** Onconetix entered into a Common Stock Purchase Agreement with an institutional investor, granting the company the right to sell up to $25 million of newly issued common stock.
*   **August 2023:** Blue Water Biotech announced a definitive agreement for the exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, generating approximately $2.7 million in gross proceeds. This also involved the issuance of new unregistered warrants for up to 4,972,428 shares of common stock.
*   **August 2022:** Blue Water Biotech closed a private placement with aggregate net cash proceeds of approximately $8.7 million.
*   **June 2025:** Onconetix effected a 1-for-85 reverse stock split to regain Nasdaq compliance. This reduced the number of outstanding shares from approximately 44.4 million to about 521,863. This is a change in share count, not necessarily an issuance of new capital, but it impacts the share structure.

** Inbound Investments:**
*   **September 2025:** Onconetix received approximately $12.9 million through a private placement of Series D Convertible Preferred Stock and warrants. Approximately $9.3 million was paid in cash, with the remainder used to offset amounts owed to investors and settle $8.8 million in debt to Veru, Inc. This looks like an inbound investment from the private placement investors.
*   **October 2024:** Onconetix secured approximately $2.0 million from a private placement of Series C Preferred Stock and warrants.
*   **October 2024:** Onconetix established a $25 million equity line of credit with an institutional investor.
*   **August 2023:** Blue Water Biotech received approximately $2.7 million in gross proceeds from the exercise of existing warrants.
*   **August 2022:** Blue Water Biotech closed a private placement resulting in approximately $8.7 million in net cash proceeds.

** Outbound Investments:**
*   **February 2026:** Onconetix announced a merger/acquisition with Realbotix (Other Commercial Services). The specific dollar amount of the outbound investment is not clearly stated, but it's a significant strategic move. The deal could transfer 75-90% of fully diluted equity to the seller, depending on Net Cash at closing, and requires at least $12.5 million of Net Cash plus a committed $125.0 million equity line. This sounds like a reverse merger where Onconetix is the acquiring shell.
*   **June 2023:** Blue Water Biotech acquired six FDA-approved drugs across various treatment areas from WraSer, LLC and Xspire Pharma, LLC for a total of $8.5 million cash consideration, payable in three tranches, and 1.0 million restricted shares of Blue Water's common stock.
*   **Prior to June 2023:** Blue Water Biotech purchased Entadfi from Veru Inc. (The background says Onconetix owns Entadfi, so this acquisition happened before the name change). The value is not immediately available here. However, mentions settlement of $8.8 million in debt to Veru, Inc. in September 2025 related to ENTADFI, which might be related to the original acquisition terms.

** Capital Expenditures:**
*   **Q4 2024:** Onconetix invested $4,000 in capital expenditures.
*   **2025:** Onconetix reported capital expenditures of $28,000.
*   **Q1 2025:** Onconetix invested $24,000 in research and development, which is typically expensed, not capitalized, so I should be careful not to confuse R&D with Capex.
*   **Nine months ended September 30, 2024:** Capital expenditures are not explicitly stated as a separate line item, but operating cash flow use was approximately $9.6 million.
*   **No clear forward-looking statements on expected capital expenditures for the upcoming year or primary focus are consistently available across the search results in summary format.** Some sources just mention general corporate purposes. The focus seems to be R&D and commercialization efforts for their products, but specific capital expenditure details for those are limited.

Let's refine and select the most significant points.

**Refinement:**
*   **Share Repurchases:** The only clear point is the 2022 authorization.
*   **Share Issuance:** The private placements in 2025 ($12.9M) and 2024 ($2.0M) are significant. The $25M equity line is an authorization for future issuance. The reverse stock split is a critical event changing the share count.
*   **Inbound Investments:** The private placements align directly with "large investments made in the company by third-parties".
*   **Outbound Investments:** The acquisition of six FDA-approved drugs for $8.5 million in cash and 1 million shares, and the planned Realbotix merger are key.
*   **Capital Expenditures:** The reported figures are quite small ($4K, $28K) which indicates minimal capital expenditures. There isn't a lot of detail about their "primary focus" beyond general statements about supporting operations and development. The 10-K for June 2025 mentions reliance on third-party manufacturers, which means less in-house capital expenditure on manufacturing facilities.

I need to ensure no disclaimers or introductory sentences and use HTML tags.
Check the timeline: "last 3-5 years" means roughly from March 2021 to March 2026. All selected events fall within this timeframe.

Final check of company identity: The results clearly refer to Onconetix, Inc. (ONCO), formerly Blue Water Biotech, Inc. (BWV), a biotechnology/pharmaceutical company, consistently with the background. The "Bluewater Bio" results are about a water technology company and have been filtered out.



	
		
			
				
					
					 Interactive Breakdown
null

null
				
			
		
	

	
		
			
				
				 Better Bets vs. Onconetix (ONCO)
				
					By Industry
					By Sector
					All Other Sectors
					Sector Best Bets
				
				
					null
					null
					null
					null
				
			
		
	

	
		
			
				
				 Latest Trefis Analyses
				 Title Date
0 DASHBOARDS  
1 Can Onconetix Stock Recover If Markets Fall? 10/17/2025
 Title
0 ARTICLES
			
		
	

	
		
			
				
				 Trade Ideas
Select ideas related to ONCO.
Unique Key Date Ticker Company Category Trade Strategy 6M Fwd Rtn 12M Fwd Rtn 12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K 02282026 QDEL QuidelOrtho Insider Insider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days 0.0% 0.0% 0.0%
CHE_2272026_Dip_Buyer_FCFYield 02272026 CHE Chemed Dip Buy DB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin 0.0% 0.0% 0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper 02272026 LLY Eli Lilly Monopoly MY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple 0.0% 0.0% 0.0%
HAE_2202026_Dip_Buyer_FCFYield 02202026 HAE Haemonetics Dip Buy DB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin 3.5% 3.5% 0.0%
IQV_2132026_Dip_Buyer_ValueBuy 02132026 IQV IQVIA Dip Buy DB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin 7.1% 7.1% -3.0%
			
		
	

	
		
			
				
				 Recent Active Movers
				
					1D
					1W
					1M
				
				
					Top Gainers
Ticker Company Mkt Cap (B) 1D Rtn YTD Rtn
AGX Argan 7.8 37.9% 81.1%
TBN Tamboran Resources 0.9 25.6% 59.4%
U Unity Software 8.3 13.5% -56.0%
ADMA ADMA Biologics 2.2 11.6% -49.3%
METC Ramaco Resources 1.0 11.4% -13.6%
MEOH Methanex 5.0 9.7% 64.8%
PTON Peloton Interactive 1.9 8.8% -28.1%
OXM Oxford Industries 0.5 8.7% 3.0%
REX REX American Resources 1.6 8.3% 47.7%
SGML Sigma Lithium 1.2 7.8% -20.7%
Top Losers
Ticker Company Mkt Cap (B) 1D Rtn YTD Rtn
BUR Burford Capital 0.9 -47.1% -53.6%
RCKT Rocket Pharmaceuticals 0.4 -19.6% 7.4%
ZBIO Zenas BioPharma 0.8 -17.8% -49.8%
BKSY BlackSky Technology 0.8 -17.2% 24.2%
PSNL Personalis 0.6 -13.4% -20.4%
SLS SELLAS Life Sciences 0.5 -11.8% 15.8%
ANAB AnaptysBio 1.6 -11.7% 18.4%
FLY Firefly Aerospace 2.2 -11.6% 6.0%
INBX Inhibrx Biosciences 0.9 -11.2% -26.1%
YOU Clear Secure 4.6 -11.2% 36.3%
					Top Gainers
Ticker Company Mkt Cap (B) 1W Rtn YTD Rtn
BCPC Balchem 5.4 610.4% 8.9%
KOD Kodiak Sciences 2.0 66.3% 32.3%
OLPX Olaplex 1.3 51.9% 50.7%
CAR Avis Budget 5.2 48.6% 15.7%
TBN Tamboran Resources 0.9 36.0% 59.4%
ELVN Enliven Therapeutics 2.4 33.8% 152.1%
TROX Tronox 1.4 30.1% 120.3%
BORR Borr Drilling 1.8 28.7% 50.1%
BRZE Braze 2.5 25.5% -32.9%
INDI Indie Semiconductor 0.6 24.6% -9.6%
Top Losers
Ticker Company Mkt Cap (B) 1W Rtn YTD Rtn
PIPR Piper Sandler Cos 1.2 -75.2% -12.4%
BUR Burford Capital 0.9 -46.2% -53.6%
WVE WAVE Life Sciences 1.1 -45.9% -62.6%
TASK TaskUs 0.6 -37.8% -15.9%
MAZE Maze Therapeutics 1.4 -36.7% -26.7%
ADMA ADMA Biologics 2.2 -35.4% -49.3%
CRCL Circle Internet 21.5 -25.7% 18.1%
PLAY Dave & Buster's Entertainment 0.3 -23.5% -39.5%
EL Estee Lauder Companies 24.3 -21.8% -35.6%
NTSK Netskope 1.9 -18.9% -55.9%
					Top Gainers
Ticker Company Mkt Cap (B) 1M Rtn YTD Rtn
SOC Sable Offshore 1.8 133.2% 104.5%
DAWN Day One Biopharmaceuticals 2.2 101.0% 129.7%
VG Venture Global 42.7 85.4% 157.4%
AAOI Applied Optoelectronics 6.2 82.9% 181.7%
TNGX Tango Therapeutics 2.1 68.9% 117.4%
AXTI AXT 2.7 63.3% 270.8%
BW Babcock & Wilcox Enterprises 1.5 61.7% 134.4%
PARR Par Pacific 3.3 61.6% 86.9%
LWLG Lightwave Logic 0.9 61.5% 123.3%
SM SM Energy 3.8 56.2% 76.5%
Top Losers
Ticker Company Mkt Cap (B) 1M Rtn YTD Rtn
WVE WAVE Life Sciences 1.1 -58.6% -62.6%
BUR Burford Capital 0.9 -51.4% -53.6%
OLMA Olema Pharmaceuticals 1.2 -44.0% -45.3%
WING Wingstop 4.3 -43.1% -35.2%
FRMI Fermi 3.7 -43.0% -22.8%
PAR PAR Technology 0.5 -43.0% -64.7%
SES SES AI 0.3 -42.6% -45.1%
USAS Americas Gold And Silver 1.5 -41.9% 7.6%
ITRG Integra Resources 0.4 -41.0% -36.2%
VITL Vital Farms 0.6 -40.6% -58.9%
				
			
		
	

	
		 More From Trefis
		
			
				Research & Analysis
				
					Latest Ideas
					Dip Buying Opportunities
					Earnings Reaction Data
				
			
		
		
			
				Invest in Strategies
				
					Invest in Trefis Strategies
					Advisor Strategies & Resources
				
			
		
		
			
				Wealth Management
				
					Help Me Invest
					Rules-Based Wealth Management
				
			
		
	

	
		
			
				 Peer Comparisons
Peers to compare with: 
				
				Financials
 ONCO EXAS MYGN OPK VTRS PFE Median
Name Onconetix Exact Sc. Myriad G. OPKO Hea. Viatris  Pfizer    
Mkt Price 1.94 - 4.28 1.12 13.05 27.04 4.28
Mkt Cap 0.0 - 0.4 0.9 15.0 153.7 0.9
Rev LTM 1 - 824 607 14,300 62,579 824
Op Inc LTM -6 - -68 -219 254 17,406 -6
FCF LTM -10 - -26 -191 1,851 9,075 -10
FCF 3Y Avg -11 - -83 -148 2,040 7,901 -11
CFO LTM -10 - 2 -179 2,316 11,704 2
CFO 3Y Avg -11 - -39 -130 2,506 11,049 -11
				Growth & Margins
 ONCO EXAS MYGN OPK VTRS PFE Median
Name Onconetix Exact Sc. Myriad G. OPKO Hea. Viatris  Pfizer    
Rev Chg LTM -67.7% - -1.6% -14.9% -3.0% -1.6% -3.0%
Rev Chg 3Y Avg - - 6.9% -15.4% -4.2% -12.0% -8.1%
Rev Chg Q -57.4% - -0.4% -19.2% 5.0% -1.2% -1.2%
QoQ Delta Rev Chg LTM -33.4% - -0.1% -5.5% 1.2% -0.3% -0.3%
Op Mgn LTM -778.2% - -8.2% -36.1% 1.8% 27.8% -8.2%
Op Mgn 3Y Avg -10,571.3% - -12.6% -30.9% 5.6% 19.6% -12.6%
QoQ Delta Op Mgn LTM -203.2% - 1.7% -2.8% -0.9% 0.9% -0.9%
CFO/Rev LTM -1,187.0% - 0.2% -29.4% 16.2% 18.7% 0.2%
CFO/Rev 3Y Avg -8,277.4% - -5.2% -19.5% 16.9% 17.8% -5.2%
FCF/Rev LTM -1,187.0% - -3.1% -31.4% 12.9% 14.5% -3.1%
FCF/Rev 3Y Avg -8,309.1% - -10.7% -21.9% 13.7% 12.7% -10.7%
				Valuation
 ONCO EXAS MYGN OPK VTRS PFE Median
Name Onconetix Exact Sc. Myriad G. OPKO Hea. Viatris  Pfizer    
Mkt Cap 0.0 - 0.4 0.9 15.0 153.7 0.9
P/S 0.7 - 0.5 1.4 1.1 2.5 1.1
P/EBIT -0.0 - -1.0 -6.5 -4.7 15.1 -1.0
P/E -0.0 - -1.1 -3.8 -4.3 19.8 -1.1
P/CFO -0.1 - 222.3 -4.8 6.5 13.1 6.5
Total Yield -2,318.3% - -91.4% -26.3% -19.6% 11.4% -26.3%
Dividend Yield 0.0% - 0.0% 0.0% 3.7% 6.4% 0.0%
FCF Yield 3Y Avg -1,413.9% - -6.2% -14.9% 14.6% 5.3% -6.2%
D/E 0.1 - 0.5 0.5 1.0 0.4 0.5
Net D/E -8.5 - 0.2 0.0 0.9 0.3 0.2
				Returns
 ONCO EXAS MYGN OPK VTRS PFE Median
Name Onconetix Exact Sc. Myriad G. OPKO Hea. Viatris  Pfizer    
1M Rtn -42.0% - -7.2% -6.7% -11.8% -2.2% -7.2%
3M Rtn -72.9% - -34.0% -13.2% 6.8% 9.6% -13.2%
6M Rtn -88.6% - -44.4% -22.8% 39.9% 17.7% -22.8%
12M Rtn -95.0% - -51.8% -34.1% 57.4% 15.0% -34.1%
3Y Rtn -100.0% - -81.0% -19.4% 56.2% -19.7% -19.7%
1M Excs Rtn -33.4% - -4.1% 1.1% -5.9% 7.6% -4.1%
3M Excs Rtn -66.3% - -26.5% -5.7% 15.7% 18.0% -5.7%
6M Excs Rtn -84.3% - -41.3% -18.1% 43.9% 22.1% -18.1%
12M Excs Rtn -107.2% - -65.0% -48.2% 40.9% 3.5% -48.2%
3Y Excs Rtn -161.8% - -143.1% -76.9% -2.9% -80.8% -80.8%
				Comparison Analyses
null
			
		
	

	
		
			
				
				 FDIC Bank Data
				Capital & Deposits
Assets
Loans
				
					Bank Capital
nullBank Deposits
null
					Bank Assets
null
					Bank Loans
null
				
			
		
	

	
		
			
				
				 FDA Approved Drugs Data
				Expand for Morenull
				Collapse to Previewnull
			
		
	

	
		
			
				
				 Financials
				Annual
Quarterly
				$ Mil | FY: 12/31 LTM 2025 2024 2023 2022 2021 2020
Period End 12/31/2025 12/31/2025 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Filing Date 3/13/2026 3/13/2026 6/2/2025 4/11/2024 3/9/2023 3/31/2022 2/23/2022

Key Financials              
Total Revenue 1 1 3 0 0 0 0
EBITDA -13 -13 -58 -37 -13 -3 -2
Operating Income -6 -6 -10 -18 -13 -3 -2
Net Income -14 -14 -59 -37 -13 -3 -2
EPS -262.13 -82.80 -9116.95 -37166.25 -15068.22 -6310.02 -3368.79

Growth Rates              
Total Revenue Growth -67.7% -67.7% 4217.3% ∞% - - -
EBITDA Growth 77.0% 77.0% -56.9% -173.7% -293.1% -110.8% -84.1%
Operating Income Growth 38.6% 38.6% 42.1% -32.4% -294.5% -110.7% -84.3%
Net Income Growth 76.1% 76.1% -56.9% -178.8% -292.7% -113.7% -94.6%

Margins              
EBITDA Margin -1626.9% -1626.9% -2281.9% -62784.1% - - -
Operating Income Margin -778.2% -778.2% -409.3% -30526.4% - - -
Net Income Margin -1721.0% -1721.0% -2325.2% -63986.5% - - -

Cash & Debt              
Total Cash 5 5 1 5 26 2 4
Total Debt 0 0 9 10 0 0 0
Net Debt / (Cash) -5 -5 9 5 -26 -2 -4

Cash Flows              
Net Cash from Operations -10 -10 -10 -14 -9 -2 -2
Free Cash from Operations -10 -10 -11 -14 -9 -2 -2

Returns to Shareholders              
Dividends 0 -0 -0 -0 -0 -0 -0
Share Repurchases 2 2 0 0 1 -0 -0
$ Mil | FY: 12/31 2025Q4 2025Q3 2025Q2 2025Q1 2024Q4 2024Q3 2024Q2 2024Q1 2023Q4 2023Q3 2023Q2 2023Q1
Period End 12/31/2025 9/30/2025 6/30/2025 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Filing Date 3/13/2026 11/13/2025 8/14/2025 6/12/2025 6/2/2025 12/10/2024 8/29/2024 5/20/2024 4/11/2024 11/17/2023 10/20/2023 5/12/2023

Key Financials Quarterly                        
Total Revenue 0 0 0 0 1 0 1 1 0 0 0 0
Ebitda 6 -8 -2 -8 -30 -3 -14 -11 -22 -5 -7 -3
Operating Income -1 -2 -1 -2 -2 -3 -2 -4 -7 -4 -3 -3
Net Income 6 -9 -2 -9 -29 -4 -14 -11 -22 -5 -7 -3
EPS 18.17 -31.25 -23.80 -225.25 -1071.87 -1245.40 -10957.95 -8534.00 -17022.75 -5189.25 -7114.27 -3047.80

Key Financials TTM                        
Total Revenue TTM 1 1 1 2 3 2 1 1 0 0 0 0
Ebitda TTM -13 -49 -44 -55 -58 -50 -52 -44 -37 -18 -17 -14
Operating Income TTM -6 -7 -8 -8 -10 -16 -18 -19 -18 -14 -13 -14
Net Income TTM -14 -49 -44 -56 -59 -52 -53 -46 -37 -18 -17 -14

Growth Rates Quarterly                        
Total Revenue Growth -57.4% -25.4% -84.9% -85.5% 1117.8% - - - - - - -
EBITDA Growth 118.9% -157.4% 84.3% 21.7% -35.5% 35.1% -105.9% -273.3% -588.3% -31.3% -56.0% -37.5%
Operating Income Growth 35.0% 21.8% 36.6% 54.0% 73.2% 41.0% 32.8% -26.3% -126.8% -16.0% 26.7% -37.6%
Net Income Growth 119.3% -129.5% 83.4% 23.1% -31.7% 28.4% -108.4% -290.6% -594.6% -38.3% -61.0% -37.5%

Margins Quarterly                        
EBITDA Margin 1870.2% -2792.8% -2014.8% -8184.1% -4212.0% -809.8% -1942.7% -1516.3% -37861.8% - - -
Operating Income Margin -422.1% -681.5% -1259.6% -1626.3% -277.0% -650.3% -300.3% -513.5% -12591.0% - - -
Net Income Margin 1867.5% -2892.7% -2227.8% -8408.8% -4134.7% -940.7% -2029.8% -1587.4% -38229.5% - - -

Cash & Debt                        
Total Cash 5 1 0 2 1 0 1 4 5 8 9 20
Total Debt 0 0 9 9 9 10 15 15 10 13 13 0
Net Debt / (Cash) -5 -1 8 7 9 10 14 11 5 5 4 -20

Cash Flows Quarterly                        
FCF from Operations -3 -3 -1 -2 -1 -1 -3 -5 -4 -3 -2 -4

Cash Flows TTM                        
FCF from Operations TTM -10 -8 -5 -7 -10 -14 -16 -14 -14 -12 -11 -12

Returns to Shareholders Quarterly                        
Dividends 0 0 0 0 0 0 0 0 0 0 0 0
Share Repurchases -0 -0 0 1 0 -0 -0 -0 -0 -0 0 0

Return on Invested Capital (ROIC) Quarterly                        
ROIC -3.6% -6.0% -3.8% -4.8% -5.7% -8.1% -14.1% -25.1% -52.7% -36.4% -27.7% -54.1%

Return on Invested Capital (ROIC) TTM                        
ROIC TTM -4.5% -5.0% -5.3% -6.0% -7.6% -12.1% -29.2% -32.7% -31.9% -27.8% -28.8% -67.7%
			
		
	

	
		
			
				
				 Segment Financials
Revenue by Segment
$ Mil 2025 2024 2023 2022 2021
Development services 2        
Product sales 0        
Total 3        



			
		
	

	
		
			
				
				 Price Behavior
				Behavior Stats
Betas Matrix
Behavior vs Other Asset Classes
				
					Price Behavior
Market Price $1.94  
Market Cap ($ Bil) 0.0  
First Trading Date 02/18/2022  
Distance from 52W High -95.1%  
    50 Days 200 Days
DMA Price $4.57 $12.81
DMA Trend down down
Distance from DMA -57.6% -84.9%
  3M 1YR
Volatility 909.9% 459.8%
Downside Capture 6.84 4.13
Upside Capture 770.44 177.18
Correlation (SPY) 14.1% 7.9%
					
ONCO Betas & Captures as of 2/28/2026


  1M 2M 3M 6M 1Y 3Y
Beta 5.77 2.12 1.39 1.88 -19.39 -10.37
Up Beta 4.34 1.45 2.21 2.49 -0.54 -0.57
Down Beta 28.54 8.93 6.45 5.22 -20.48 -15.61
Up Capture -450% -286% -339% -110% -58% -7%
Bmk +ve Days 9 20 31 70 142 431
Stock +ve Days 9 20 24 53 106 291
Down Capture 551% 284% 315% 205% -398% 102%
Bmk -ve Days 12 21 30 54 109 320
Stock -ve Days 12 20 36 69 140 440


[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
					
						
							1Y
							5Y
							10Y
						
						
							Based On 1-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with ONCO
ONCO -95.7% 457.6% 0.28 -
Sector ETF (XLV) 0.3% 17.6% -0.13 7.2%
Equity (SPY) 14.5% 18.9% 0.59 7.9%
Gold (GLD) 50.2% 27.7% 1.46 8.8%
Commodities (DBC) 17.8% 17.6% 0.85 4.8%
Real Estate (VNQ) 0.4% 16.4% -0.15 1.5%
Bitcoin (BTCUSD) -23.7% 44.2% -0.49 7.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
							Based On 5-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with ONCO
ONCO -92.8% 294.3% -0.24 -
Sector ETF (XLV) 6.0% 14.5% 0.23 3.8%
Equity (SPY) 11.8% 17.0% 0.54 6.2%
Gold (GLD) 20.7% 17.7% 0.96 5.5%
Commodities (DBC) 11.6% 18.9% 0.50 3.4%
Real Estate (VNQ) 3.0% 18.8% 0.07 5.7%
Bitcoin (BTCUSD) 4.0% 56.6% 0.29 3.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
							Based On 10-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with ONCO
ONCO -73.1% 294.3% -0.24 -
Sector ETF (XLV) 9.7% 16.5% 0.48 3.8%
Equity (SPY) 14.0% 17.9% 0.67 6.2%
Gold (GLD) 13.3% 15.8% 0.70 5.5%
Commodities (DBC) 8.2% 17.6% 0.39 3.4%
Real Estate (VNQ) 4.7% 20.7% 0.19 5.7%
Bitcoin (BTCUSD) 66.4% 66.8% 1.06 3.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
						
					
				
			
		
		
			
				
				 Short Interest
Short Interest: As Of Date 3132026
Short Interest: Shares Quantity 0.3 Mil
Short Interest: % Change Since 2282026 586.4%
Average Daily Volume 0.7 Mil
Days-to-Cover Short Interest 1
Basic Shares Quantity 0.3 Mil
Short % of Basic Shares 83.4%
			
		
	

	
		
			
				 Returns Analyses
 Title
0 Can Onconetix Stock Recover If Markets Fall?
			
		
	

	
		
			
				
				 Earnings Returns History
				Expand for More  Forward Returns
Earnings Date 1D Returns 5D Returns 21D Returns
SUMMARY STATS      
# Positive 0 0 0
# Negative 0 0 0
Median Positive      
Median Negative      
Max Positive      
Max Negative      
				Collapse to Preview  Forward Returns
Earnings Date 1D Returns 5D Returns 21D Returns
SUMMARY STATS      
# Positive 0 0 0
# Negative 0 0 0
Median Positive      
Median Negative      
Max Positive      
Max Negative      
			
		
		
			
				
				 SEC Filings
				Expand for MoreReport Date Filing Date Filing
12/31/2025 03/13/2026 10-K
09/30/2025 11/13/2025 10-Q
06/30/2025 08/14/2025 10-Q
03/31/2025 06/12/2025 10-Q
12/31/2024 06/02/2025 10-K
09/30/2024 12/10/2024 10-Q
06/30/2024 08/29/2024 10-Q
03/31/2024 05/20/2024 10-Q
12/31/2023 04/11/2024 10-K
09/30/2023 11/17/2023 10-Q
06/30/2023 10/20/2023 10-Q
03/31/2023 05/12/2023 10-Q
12/31/2022 03/09/2023 10-K
09/30/2022 11/14/2022 10-Q
06/30/2022 08/15/2022 10-Q
03/31/2022 05/13/2022 10-Q
				Collapse to PreviewReport Date Filing Date Filing
12/31/2025 03/13/2026 10-K
09/30/2025 11/13/2025 10-Q
06/30/2025 08/14/2025 10-Q
03/31/2025 06/12/2025 10-Q
12/31/2024 06/02/2025 10-K
09/30/2024 12/10/2024 10-Q
06/30/2024 08/29/2024 10-Q
03/31/2024 05/20/2024 10-Q
12/31/2023 04/11/2024 10-K
09/30/2023 11/17/2023 10-Q
06/30/2023 10/20/2023 10-Q
03/31/2023 05/12/2023 10-Q
12/31/2022 03/09/2023 10-K
09/30/2022 11/14/2022 10-Q
06/30/2022 08/15/2022 10-Q
03/31/2022 05/13/2022 10-Q
12/31/2021 03/31/2022 10-K
09/30/2021 02/23/2022 424B4
			
		
	

	
		
			
				
				 Recent Forward Guidance [BETA]
				Latest: null Earnings Reported N/A/N/A/N/A | Prior: null Earnings Reported N/A/N/A/N/A
				null
			
		
	

	
		
			
				
				 Insider Activity
				Expand for Morenull
				Collapse to Previewnull
			
		
	
	
	
		
			
				
				 ONCO Trade Sentinel
				
				
					
						
					
					
						
					
					
						
					
					
						
					
				
				
				
				
				
					
						
							
								
									
										Stock Conviction									
										null
									
								
								
									 
									 	CONVICTION RATIONALE
										null
									 
								
								
									
										
											STOCK ARCHETYPE
											null
										
										null
									
								
							

							
								
									
										INVESTMENT THESIS
										null
										null
										
										
											Mechanism:
											null
										
										
										
											Supporting Evidence:
											
												
											
										
									
								
								
								
									
										PRIMARY RISK
										null
										null
										
										 
											Mechanism:
											null
										
										
										
											Supporting Evidence:
											
												 
											
										
									
								
							

							
								 Key KPI Watchlist
								 
									
										
											
												
													KPI
													Threshold
													Rationale
												
											
											
												
											
										
									
								 
							

						
					

					
						
							
								Core Investment Debate
								
							

							
								
									
										BULL VIEW
										
									
								
								
									
										CORE TENSION
										
										
										PREVAILING SENTIMENT
										
										
									
								
								
									
										BEAR VIEW
										
									
								
							

							
								Next 6 months: Risks and Catalysts
								
									
										
											
												
													Timeline
													Event & Metric To Watch
												
											
											
												
											
										
									
								
							

							
								Key Events in Last 6 Months
								
									
										
											
												
													Date
													Event
													Stock Impact
												
											
											
												
											
										
									
								
							

							
								Risk Management
								
									
										
											 Position Sizing
											null
											null
											null
										
										
											 Diversification Alternatives
											
												
											
										
									
								
							
						
					

					
						
							How Is The Market Pricing ONCO?

							
								
									
								
							

							
								
									
								
							

							
								
									
										 What will confirm the thesis
										
									
								

								
									
										 What will damage the thesis
										
									
								

								
									
										 Noise: Real but irrelevant to thesis
										
									
								
							

							
								Repricing Catalyst
								
							

							
								What ONCO Makes & Who Pays

								
									
										TTM figures based on 
									
								
								
								
									
								
							

							
								ONCO Evolution: Price Return by Era
								
								
								

								
									
										
									
								
							

						
					

					
						
						
							
							
								
								

								
									
										① Structure
										
											0
											
										
										
									
									
										② Volume / Momentum
										
											0
											
										
										
									
									
										③ Catalyst
										
											0
											
										
										
									
								

								
									Combined Score
									
										
									
									0 / 12
								
							

							
								
									1
									Price Structure & Trend
									 · 
									▾
								
								
									
										▲
										
									

									
										
											Current
											$
											
											
										
										
											20D SMA
											$
											
											Below
										
										
											50D SMA
											$
											Slope: %
											Below
										
										
											200D SMA
											$
											Slope: %
											Below
										
									

									
										✕
										 —  trading days ago
									

									
										
											52W High
											$
										
										
											From 52W High
											%
										
										
											All-Time High
											$
										
										
											From ATH
											%
										
									
									
										
											52W Low
											$
										
										
											From 52W Low
											%
										
									
								
							

							
								
									2
									Momentum
									
									▾
								
								
									
										↑
										
									

									
										
											5D
											%
											
										
										
											20D
											%
											
										
										
											63D
											%
											
										
										
											126D
											%
											
										
										
											252D
											%
											
										
									
								
							

							
								
									3
									Relative Strength vs. SPY
									
									▾
								
								
									
										↑
										
									

									
										
											20D
											
											%
										
										
											63D
											
											%
										
										
											126D
											
											%
										
										
											252D
											
											%
										
									

									
										
											RS Trend
											%
										
										
											RS Character
											
										
									
								
							

							
								
									4
									Institutional Footprint & Volume
									
									▾
								
								
									
										↓
										
									
									
										◈
										
									

									
										
											Score
											
										
										
											Up/Down Vol 20D
											
										
										
											Up/Down Vol 60D
											
										
									
									
										
											OBV Slope 20D
											
										
										
											OBV Slope 60D
											
										
										
											Hi-Conv Up Days
											
											Past 60D
										
										
											Hi-Conv Down Days
											
											Past 60D
										
									
									
										
											Volume Trend
											
											20D avg vs 60D avg
										
										
									
								
							

							
								
									5
									Volatility
									
									▾
								
								
									
										≈
										
									
									
										
											HV 20D
											%
										
										
											HV 60D
											%
										
										
											HV 252D
											%
										
									
									
										
											Compression Ratio
											
										
										
											ATR 14D
											%
										
									
								
							

							
								
									6
									Key Price Levels
									Range · Vol 
									▾
								
								
									
										◈
										
									
									
										
											Nearest Resistance
											$
											% away ·  touches
										
										
											Nearest Support
											$
											% away ·  touches
										
										
											2nd Support
											$
											 touches
										
										
											Risk / Reward
											×
										
									
									
										
											Approach Volume
											
										
										
											Current Price
											$
										
									
								
							

							
								
									7
									Earnings Reaction History
									
									▾
								
								
									
										★
										
									
									
										
											
												
												
											
											
												%
												Earnings Day Return · Vol Spike ×
												
													
														5D
														%
													
													
														10D
														%
													
													
														20D
														%
													
													
														Post Vol
														×
													
												
												
												
											
										
										
											
												
												
											
											
												%
												Earnings Day Return · Vol Spike ×
												
													
														5D
														%
													
													
														10D
														%
													
													
														20D
														%
													
													
														Post Vol
														×
													
												
												
												
											
										
									
								
							

							
								
									8
									How the Verdict Is Derived
									Three Pillars
									▾
								
								
									
										
											
												Pillar
												Score
											
										
										
											
												① Structure
												0
											
											
												② Vol / Mom
												0
											
											
												③ Catalyst
												0
											
										
									
									
										ℹ
										
											Bull Pillars: 0 ·
											Bear Pillars: 0 ·
											Combined Score: 0 →
											
										
									
								
							

							
								Price Intelligence is derived from price-volume pattern analysis only. All moving averages are simple (SMA). Relative strength benchmarked against SPY.
							
						
					
					
				
			
		
	
	
	
		
			
				
				 Industry Resources
Health Care Resources
U.S. National Library of Medicine
ClinicalTrials.gov
Modern Healthcare
Healthcare Dive
Fierce Healthcare
Health Affairs
Health Data Management
FDA Tracker
Biotechnology Resources
Fierce Biotech
Nature Biotechnology
Genetic Engineering & Biotechnology News
Biotechnology Innovation Organization
BioWorld
BioTechniques
HBS Biotechnology Publications
			
		
		
			
				
				 External Quote Links
0 Y Finance Barrons
1 TradingView Morningstar
2 SeekingAlpha ValueLine
3 Motley Fool Robinhood
4 CNBC Etrade
5 MarketWatch Unusual Whales
6 YCharts Perplexity Finance
7 FinViz  

Prefer one of these to Trefis? Tell us why.

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

	Title	Date
0	DASHBOARDS
1	Can Onconetix Stock Recover If Markets Fall?	10/17/2025

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K	02282026	QDEL	QuidelOrtho	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
CHE_2272026_Dip_Buyer_FCFYield	02272026	CHE	Chemed	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper	02272026	LLY	Eli Lilly	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	0.0%	0.0%	0.0%
HAE_2202026_Dip_Buyer_FCFYield	02202026	HAE	Haemonetics	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	3.5%	3.5%	0.0%
IQV_2132026_Dip_Buyer_ValueBuy	02132026	IQV	IQVIA	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.1%	7.1%	-3.0%

	ONCO	EXAS	MYGN	OPK	VTRS	PFE	Median
Name	Onconetix	Exact Sc.	Myriad G.	OPKO Hea.	Viatris	Pfizer
Mkt Price	1.94	-	4.28	1.12	13.05	27.04	4.28
Mkt Cap	0.0	-	0.4	0.9	15.0	153.7	0.9
Rev LTM	1	-	824	607	14,300	62,579	824
Op Inc LTM	-6	-	-68	-219	254	17,406	-6
FCF LTM	-10	-	-26	-191	1,851	9,075	-10
FCF 3Y Avg	-11	-	-83	-148	2,040	7,901	-11
CFO LTM	-10	-	2	-179	2,316	11,704	2
CFO 3Y Avg	-11	-	-39	-130	2,506	11,049	-11

Market Price	$1.94
Market Cap ($ Bil)	0.0
First Trading Date	02/18/2022
Distance from 52W High	-95.1%
	50 Days	200 Days
DMA Price	$4.57	$12.81
DMA Trend	down	down
Distance from DMA	-57.6%	-84.9%
	3M	1YR
Volatility	909.9%	459.8%
Downside Capture	6.84	4.13
Upside Capture	770.44	177.18
Correlation (SPY)	14.1%	7.9%

	1M	2M	3M	6M	1Y	3Y
Beta	5.77	2.12	1.39	1.88	-19.39	-10.37
Up Beta	4.34	1.45	2.21	2.49	-0.54	-0.57
Down Beta	28.54	8.93	6.45	5.22	-20.48	-15.61
Up Capture	-450%	-286%	-339%	-110%	-58%	-7%
Bmk +ve Days	9	20	31	70	142	431
Stock +ve Days	9	20	24	53	106	291
Down Capture	551%	284%	315%	205%	-398%	102%
Bmk -ve Days	12	21	30	54	109	320
Stock -ve Days	12	20	36	69	140	440

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ONCO
ONCO	-95.7%	457.6%	0.28	-
Sector ETF (XLV)	0.3%	17.6%	-0.13	7.2%
Equity (SPY)	14.5%	18.9%	0.59	7.9%
Gold (GLD)	50.2%	27.7%	1.46	8.8%
Commodities (DBC)	17.8%	17.6%	0.85	4.8%
Real Estate (VNQ)	0.4%	16.4%	-0.15	1.5%
Bitcoin (BTCUSD)	-23.7%	44.2%	-0.49	7.6%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ONCO
ONCO	-92.8%	294.3%	-0.24	-
Sector ETF (XLV)	6.0%	14.5%	0.23	3.8%
Equity (SPY)	11.8%	17.0%	0.54	6.2%
Gold (GLD)	20.7%	17.7%	0.96	5.5%
Commodities (DBC)	11.6%	18.9%	0.50	3.4%
Real Estate (VNQ)	3.0%	18.8%	0.07	5.7%
Bitcoin (BTCUSD)	4.0%	56.6%	0.29	3.5%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ONCO
ONCO	-73.1%	294.3%	-0.24	-
Sector ETF (XLV)	9.7%	16.5%	0.48	3.8%
Equity (SPY)	14.0%	17.9%	0.67	6.2%
Gold (GLD)	13.3%	15.8%	0.70	5.5%
Commodities (DBC)	8.2%	17.6%	0.39	3.4%
Real Estate (VNQ)	4.7%	20.7%	0.19	5.7%
Bitcoin (BTCUSD)	66.4%	66.8%	1.06	3.5%

Short Interest: As Of Date	3132026
Short Interest: Shares Quantity	0.3 Mil
Short Interest: % Change Since 2282026	586.4%
Average Daily Volume	0.7 Mil
Days-to-Cover Short Interest	1
Basic Shares Quantity	0.3 Mil
Short % of Basic Shares	83.4%

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
SUMMARY STATS
# Positive	0	0	0
# Negative	0	0	0
Median Positive
Median Negative
Max Positive
Max Negative

Report Date	Filing Date	Filing
12/31/2025	03/13/2026	10-K
09/30/2025	11/13/2025	10-Q
06/30/2025	08/14/2025	10-Q
03/31/2025	06/12/2025	10-Q
12/31/2024	06/02/2025	10-K
09/30/2024	12/10/2024	10-Q
06/30/2024	08/29/2024	10-Q
03/31/2024	05/20/2024	10-Q
12/31/2023	04/11/2024	10-K
09/30/2023	11/17/2023	10-Q
06/30/2023	10/20/2023	10-Q
03/31/2023	05/12/2023	10-Q
12/31/2022	03/09/2023	10-K
09/30/2022	11/14/2022	10-Q
06/30/2022	08/15/2022	10-Q
03/31/2022	05/13/2022	10-Q

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Onconetix (ONCO)

Market Price (3/30/2026): $1.52 | Market Cap: $0.5 MilSector: Health Care | Industry: Biotechnology

Onconetix (ONCO)

Market Price (3/30/2026): $1.52Market Cap: $0.5 MilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Onconetix (ONCO)

Key Risks to Onconetix (ONCO)

Interactive Breakdown

Better Bets vs. Onconetix (ONCO)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

ONCO Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

null

Diversification Alternatives

Repricing Catalyst

Industry Resources

Market Price (3/30/2026): $1.52 | Market Cap: $0.5 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (3/30/2026): $1.52
Market Cap: $0.5 Mil
Sector: Health Care
Industry: Biotechnology